🎉 M&A multiples are live!
Check it out!

Verastem Valuation Multiples

Discover revenue and EBITDA valuation multiples for Verastem and similar public comparables like Pharming, Galapagos, and Julphar.

Verastem Overview

About Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.


Founded

2010

HQ

United States of America
Employees

80

Website

verastem.com

Financials

LTM Revenue $11.8M

LTM EBITDA n/a

EV

$200M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Verastem Financials

Verastem has a last 12-month revenue of $11.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Verastem achieved revenue of $10.0M and an EBITDA of -$126M.

Verastem expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Verastem valuation multiples based on analyst estimates

Verastem P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $10.0M XXX XXX XXX
Gross Profit $2.6M n/a XXX XXX XXX
Gross Margin Infinity% NaN% XXX XXX XXX
EBITDA -$83.2M -$126M XXX XXX XXX
EBITDA Margin -Infinity% -1259% XXX XXX XXX
Net Profit -$73.8M -$87.4M XXX XXX XXX
Net Margin -Infinity% -874% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Verastem Stock Performance

As of April 15, 2025, Verastem's stock price is $5.

Verastem has current market cap of $246M, and EV of $200M.

See Verastem trading valuation data

Verastem Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$200M $246M XXX XXX XXX XXX $-3.26

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Verastem Valuation Multiples

As of April 15, 2025, Verastem has market cap of $246M and EV of $200M.

Verastem's trades at 16.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Verastem's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Verastem and 10K+ public comps

Verastem Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $200M XXX XXX XXX
EV/Revenue 20.0x XXX XXX XXX
EV/EBITDA -1.6x XXX XXX XXX
P/E -1.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Verastem Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Verastem Valuation Multiples

Verastem's NTM/LTM revenue growth is 180%

Verastem's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Verastem's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Verastem's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Verastem and other 10K+ public comps

Verastem Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -1259% XXX XXX XXX XXX
EBITDA Growth 51% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1079% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 813% XXX XXX XXX XXX
Opex to Revenue 1250% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Verastem Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Verastem M&A and Investment Activity

Verastem acquired  XXX companies to date.

Last acquisition by Verastem was  XXXXXXXX, XXXXX XXXXX XXXXXX . Verastem acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Verastem

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Verastem

When was Verastem founded? Verastem was founded in 2010.
Where is Verastem headquartered? Verastem is headquartered in United States of America.
How many employees does Verastem have? As of today, Verastem has 80 employees.
Who is the CEO of Verastem? Verastem's CEO is Mr. Daniel Paterson.
Is Verastem publicy listed? Yes, Verastem is a public company listed on NAS.
What is the stock symbol of Verastem? Verastem trades under VSTM ticker.
When did Verastem go public? Verastem went public in 2012.
Who are competitors of Verastem? Similar companies to Verastem include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Verastem? Verastem's current market cap is $246M
What is the current revenue of Verastem? Verastem's last 12-month revenue is $11.8M.
What is the current EV/Revenue multiple of Verastem? Current revenue multiple of Verastem is 16.9x.
Is Verastem profitable? Yes, Verastem is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.